摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(2-pyrrolidin-1-ylethyl)-3H-benzimidazol-5-ylamine | 848779-59-9

中文名称
——
中文别名
——
英文名称
3-(2-pyrrolidin-1-ylethyl)-3H-benzimidazol-5-ylamine
英文别名
3-(2-Pyrrolidin-1-ylethyl)benzimidazol-5-amine
3-(2-pyrrolidin-1-ylethyl)-3H-benzimidazol-5-ylamine化学式
CAS
848779-59-9
化学式
C13H18N4
mdl
——
分子量
230.313
InChiKey
WHHFSLVQKHLXFI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    440.4±51.0 °C(Predicted)
  • 密度:
    1.28±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    17
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.46
  • 拓扑面积:
    47.1
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    3-(2-pyrrolidin-1-ylethyl)-3H-benzimidazol-5-ylamine4-苄氧基苯乙酸N-甲基吗啉1-(3-二甲基氨基丙基)-3-乙基碳二亚胺1-羟基苯并三唑一水物 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 以0.0580 g的产率得到2-(4-Benzyloxy-benzylamino)-N-[3-(2-pyrrolidin-1-yl-ethyl)-3H-benzoimidazol-5-yl]-acetamide
    参考文献:
    名称:
    Identification of 2-(4-Benzyloxyphenyl)-N- [1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-6-yl]acetamide, an Orally Efficacious Melanin-Concentrating Hormone Receptor 1 Antagonist for the Treatment of Obesity
    摘要:
    Optimization of a high-throughput screening hit against melanin-concentrating hormone receptor 1 (MCHrl) led to the discovery of 2-(4-benzyloxy-phenyl)-N-[1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-6-yl]acetamide (7a). This compound was found to be a high-affinity ligand for MCHrl and a potent inhibitor of MCH-mediated Ca2+ release, showed good plasma and CNS exposure upon oral dosing in diet-induced obese mice, and is the first reported MCHrl antagonist that is efficacious upon oral dosing in a chronic model of weight loss.(1)
    DOI:
    10.1021/jm0490890
  • 作为产物:
    描述:
    6-nitro-1-(2-pyrrolidin-1-ylethyl)-1H-benzimidazole 在 铁粉氯化铵 作用下, 以 乙醇 为溶剂, 生成 3-(2-pyrrolidin-1-ylethyl)-3H-benzimidazol-5-ylamine
    参考文献:
    名称:
    Identification of 2-(4-Benzyloxyphenyl)-N- [1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-6-yl]acetamide, an Orally Efficacious Melanin-Concentrating Hormone Receptor 1 Antagonist for the Treatment of Obesity
    摘要:
    Optimization of a high-throughput screening hit against melanin-concentrating hormone receptor 1 (MCHrl) led to the discovery of 2-(4-benzyloxy-phenyl)-N-[1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-6-yl]acetamide (7a). This compound was found to be a high-affinity ligand for MCHrl and a potent inhibitor of MCH-mediated Ca2+ release, showed good plasma and CNS exposure upon oral dosing in diet-induced obese mice, and is the first reported MCHrl antagonist that is efficacious upon oral dosing in a chronic model of weight loss.(1)
    DOI:
    10.1021/jm0490890
点击查看最新优质反应信息

文献信息

  • Substituierte Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
    申请人:Bayer Schering Pharma Aktiengesellschaft
    公开号:EP2141163A1
    公开(公告)日:2010-01-06
    Die Erfindung betrifft Thiazolidinone der allgemeinen Formel ( I ) wobei R1, Q und X in den Ansprüchen definiert sind, deren Herstellung und Verwendung als Inhibitoren der Polo Like Kinase (Plk) zur Behandlung verschiedener Erkrankungen, sowie Zwischenprodukte zu deren Herstellung.
    本发明涉及通式 ( I ) 的噻唑烷酮化合物 其中 R1、Q 和 X 在权利要求中定义,它们的制备和用作治疗各种疾病的类 polo 激酶(Plk)抑制剂,以及制备它们的中间体。
  • Identification of 2-(4-Benzyloxyphenyl)-<i>N</i>- [1-(2-pyrrolidin-1-yl-ethyl)-1<i>H</i>-indazol-6-yl]acetamide, an Orally Efficacious Melanin-Concentrating Hormone Receptor 1 Antagonist for the Treatment of Obesity
    作者:Andrew J. Souers、Ju Gao、Michael Brune、Eugene Bush、Dariusz Wodka、Anil Vasudevan、Andrew S. Judd、Mathew Mulhern、Sevan Brodjian、Brian Dayton、Robin Shapiro、Lisa E. Hernandez、Kennan C. Marsh、Hing L. Sham、Christine A. Collins、Philip R. Kym
    DOI:10.1021/jm0490890
    日期:2005.3.1
    Optimization of a high-throughput screening hit against melanin-concentrating hormone receptor 1 (MCHrl) led to the discovery of 2-(4-benzyloxy-phenyl)-N-[1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-6-yl]acetamide (7a). This compound was found to be a high-affinity ligand for MCHrl and a potent inhibitor of MCH-mediated Ca2+ release, showed good plasma and CNS exposure upon oral dosing in diet-induced obese mice, and is the first reported MCHrl antagonist that is efficacious upon oral dosing in a chronic model of weight loss.(1)
查看更多